LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

Condition(s) studied

Study summary

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

Eligibility

Primary outcome measure(s)

• NGS Testing — through study completion, an average of 5 years
  To assess molecular biomarker testing and indicators of the quality of care in patients with lung cancer

Trial sites (1)

More Karl Landsteiner Institute for Lung Research and Pneumological Oncology trials in Austria

Other trials for the same condition